Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)

- Participants, aged 40 years or older

- Diagnosis of IPF, within 8 years prior to Screening

- FVC % predicted ≥45%; historical FVC for entry in the study is permitted if within 1 month of screening

- Diffusing capacity for carbon monoxide DLco (hemoglobin-adjusted) ≥30%; historical DLco for entry in the study is permitted if within 1 month of Screening

- Participants currently receiving treatment for IPF with nintedanib or pirfenidone are permitted, if on a stable dose for at least 3 months

- Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDA

- Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio <0.7 at Screening

- Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progression

- Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of Screening

- Smoking of any kind within 3 months of Screening